Ensysce Biosciences Inc.

46 articles with Ensysce Biosciences Inc.

• Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

  11/15/2021

  Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the third quarter of 2021 and recent corporate updates.

• Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing

  11/8/2021

  Ensysce Biosciences, Inc. announced today that it has completed its previously announced private placement under a securities purchase agreement with institutional investors (“Investors”) for senior secured convertible notes

• Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

  10/26/2021

  Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021.

• Ensysce Biosciences Announces $15 Million Convertible Note Financing

  9/27/2021

  Ensysce Biosciences, Inc. announced today that it has entered into a securities purchase agreement with institutional investors (“Investors”) in the form of senior secured convertible notes

• Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614

  9/8/2021

  Ensysce Biosciences, Inc. announced that it has enrolled the first cohort of subjects in a clinical study PF614-102 entitled “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics and Safety of Multiple-Ascending Oral Doses of PF614 and the Food Effect and Bioavailability/Bioequivalence of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.”

• Ensysce Biosciences Sets September 2021 Conference Schedule

  8/31/2021

  Ensysce Biosciences, Inc. is scheduled to participate at the following industry and financial conferences during September 2021: 10th Annual Gateway Conference Date and Time : Held virtually on September 8-9, 2021

• Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021

  8/19/2021

  Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced it will sponsor a satellite symposium at PAINWeek 2021 on Thursday, September 9 from 3:40 p.m. to 4:30 p.m. Eastern Time (12:40 p.m. to 1:30 p.m. Pacific Time) in Castellana 1 Ballroom, The Cosmopolitan of Las Vegas

• Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

  8/16/2021

  Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the second quarter of 2021 and recent corporate updates.

• Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof”

  8/5/2021

  Ensysce Biosciences, Inc., a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, announced that the United States Patent and Trademark Office has granted Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof.

• Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development

  7/26/2021

  Ensysce Biosciences, Inc. has appointed David J. Kovacs to the new position of VP Public Policy and David Tanzer to the new position of VP Strategic Development, both effective July 22, 2021.

• Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021

  7/21/2021

  Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that it will host a virtual investor day on Tuesday, July 27, 2021 from 11:00 am to 12:00 pm EDT.

• Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection

  7/8/2021

  Ensysce Biosciences, Inc. today announced receipt of the 3rd year award of a multi-year grant from the National Institute on Drug Abuse (NIDA). This award will provide $2.8 million to initiate a Phase 1 study of the first MPAR™ overdose protection program.

• Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021

  7/1/2021

  Ensysce Biosciences, Inc. announced that, in connection with the closing of its previously announced merger with Leisure Acquisition Corp., the combined company, Ensysce Biosciences, Inc., will commence trading its common stock and warrants under the ticker symbols “LACQ” and “LACQW,” respectively, on the OTC Market on July 1, 2021.

• Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021

  7/1/2021

  Ensysce Biosciences, Inc. announced that the Company will begin trading its common stock under the ticker symbol “ENSC” on The Nasdaq Capital Market and warrants under the ticker symbol “ENSCW” on the OTC Market on July 2, 2021.

• Ensysce Biosciences Announces Closing of Merger

  6/30/2021

  Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC) (OTC: ENSCW) today announced that it has closed its previously announced merger with Leisure Acquisition Corp. (“LACQ”).

• Ensysce Biosciences’ Covistat Subsidiary “At Home Coronavirus Pill” Commencing to Phase 2 clinical developmentCovistat to present pre-clinical data at American Thoracic Society annual meeting, May 14-19, 2021

  5/7/2021

  Ensysce Biosciences, Inc. (“Ensysce”), which has entered into an agreement for a business combination with Leisure Acquisition Corp. (“LACQ”) (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that Ensysce’s subsidiary, Covistat, will be presenting at the upcoming American Thoracic Society (ATS) Annual Meeting

• Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection

  4/29/2021

  Ensysce Biosciences, Inc. (“Ensysce”) and Leisure Acquisition Corp. (“LACQ”) (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that Ensysce has received U.S. Food and Drug Administration (“FDA”) allowance for an Investigational New Drug (IND) application for PF614-MPAR

• Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences

  4/15/2021

  Additional Contract Broadens and Further Strengthens Customer Product Portfolio

• Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer

  2/18/2021

  Ensysce Biosciences Inc. ("Ensysce"), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, and Leisure Acquisition Corp. (NASDAQ: LACQ) ("LACQ") today announced the appointment of David Humphrey to Ensysce's management team as its Chief Financial Officer.

• Ensysce Biosciences, Inc. And Leisure Acquisition Corp. To Host Investor Call Regarding Business Combination On February 3, 2021

  2/2/2021

  - Ensysce Biosciences, a clinical stage biopharmaceutical company with a mission to solve prescription drug abuse, is focused on launching a new class of opioid pain therapeutics